Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes

Nayyar Iqbal,1 Elsie Allen,1 Peter Öhman2 1Bristol-Myers Squibb, Princeton, NJ, USA; 2AstraZeneca, Wilmington, DE, USA Background: Treatment decisions for older patients with type 2 diabetes mellitus must balance glycemic control and adverse event risk. The objective of this study was to...

Full description

Bibliographic Details
Main Authors: Iqbal N, Allen E, Öhman P
Format: Article
Language:English
Published: Dove Medical Press 2014-09-01
Series:Clinical Interventions in Aging
Subjects:
elderly
glyburide
metformin
saxagliptin
thiazolidinedione
Online Access:https://www.dovepress.com/long-term-safety-and-tolerability-of-saxagliptin-add-on-therapy-in-old-peer-reviewed-article-CIA

Internet

https://www.dovepress.com/long-term-safety-and-tolerability-of-saxagliptin-add-on-therapy-in-old-peer-reviewed-article-CIA

Similar Items